Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Opthea Limited (OPT.AX)
South Yarra, VIC, AU
Opthea Limited is an Australian clinical-stage biopharmaceutical company focused on developing and commercializing therapies primarily for eye diseases. The foundation of its development efforts lies in its intellectual property portfolio, which targets Vascular Endothelial Growth Factors (VEGF-C, VEGF-D, and VEGF Receptor-3). This technology is designed to address conditions linked to the growth of blood and lymphatic vessels, as well as vascular leakage. The company's leading asset, OPT 302, is a soluble form of VEGFR3 currently undergoing clinical trials. This novel therapy aims to treat wet neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). OPT 302 is distinguished as a first-in-class VEGF-C/D inhibitor, intended to be used in conjunction with VEGF-A inhibitors for the treatment of wet AMD and various other retinal diseases. Originally incorporated in 1984 as Circadian Technologies Limited, the company rebranded to Opthea Limited in December 2015 and is headquartered in South Yarra, Australia.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Owner Earnings
Owner's Earnings history not available.
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Australian Shares Index ETF VAS.AX | 0.02% | 3.56M | 0.07% |
| 2 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 1.53M | 0.06% |
| 3 | Vanguard FTSE Pacific ETF VPL | 0.00% | 589.7K | 0.07% |
| 4 | Vanguard FTSE Developed Asia Pacific All Cap Index ETF VA.TO | 0.00% | 5.0K | 0.22% |
| 5 | Vanguard FTSE Developed All Cap ex U.S. Index ETF VDU.TO | 0.00% | 7.7K | 0.22% |
| 6 | Vanguard FTSE Developed All Cap ex U.S. Index ETF (CAD-hedged) VEF.TO | 0.00% | 11.9K | 0.22% |
| 7 | Vanguard FTSE Developed Markets ETF VEA | 0.00% | 4.03M | 0.03% |
| 8 | Vanguard ESG International Stock ETF VSGX | 0.00% | 79.0K | 0.10% |
| 9 | Vanguard FTSE Developed All Cap ex North America Index ETF (CAD-hedged) VI.TO | 0.00% | 7.5K | 0.22% |
| 10 | Vanguard FTSE Developed All Cap ex North America Index ETF VIU.TO | 0.00% | 86.7K | 0.23% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for OPT.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
